Molecular structure of Ozagrel, CAS Number: 82571-53-7
Ozagrel (CAS 82571-53-7)
See product citations (5)
Alternate Names:
Ozagrel, OKY-046
Application:
Ozagrel is a potent and selective thromboxane A2 inhibitor
CAS Number:
82571-53-7
Purity:
98%
Molecular Weight:
228.2
Molecular Formula:
C13H12N2O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ozagrel, an antithrombic drug, is a potent and selective thromboxane A2 inhibitor highly active in human platelets. Found to induce apoptosis in T24 and TCC-SUP bladder cancer cells. Ozagrel improved locomotor activity and coordination in ischemia-reperfusion injured mice models and has potential therapeutic usage for stroke. Reported to inhibit pulmonary thromboxane B2 delivery blocking the increase in systemic vascular resistance. Also shown to inhibit phenolase activities of mushroom tyrosinase.
Ozagrel (CAS 82571-53-7) References
- Effect of ozagrel on locomotor and motor coordination after transient cerebral ischemia in experimental animal models. | Ichikawa, K., et al. 1999. Pharmacology. 59: 257-65. PMID: 10529658
- Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban. | Moriguchi, A., et al. 2004. J Pharmacol Exp Ther. 308: 1094-101. PMID: 14634048
- Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger. | Imamura, T., et al. 2003. Arzneimittelforschung. 53: 688-94. PMID: 14650360
- Selective thromboxane A2 synthase inhibition by OKY-046 prevents cardiopulmonary dysfunction after ovine smoke inhalation injury. | Westphal, M., et al. 2005. Anesthesiology. 102: 954-61. PMID: 15851882
- Ibuprofen or ozagrel increases NO release and l-nitro arginine induces TXA(2) release from cultured porcine basilar arterial endothelial cells. | Miyamoto, A., et al. 2007. Vascul Pharmacol. 46: 85-90. PMID: 17113355
- Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. | Moussa, O., et al. 2008. Oncogene. 27: 55-62. PMID: 17603559
- Ozagrel attenuates early streptozotocin-induced constriction of arterioles in the mouse retina. | Wright, WS. and Harris, NR. 2008. Exp Eye Res. 86: 528-36. PMID: 18262522
- Ozagrel reverses streptozotocin-induced constriction of arterioles in rat retina. | Lee, S., et al. 2008. Microvasc Res. 76: 217-23. PMID: 18718478
- In vitro effect of ozagrel on mushroom tyrosinase. | Li, SB., et al. 2009. Protein J. 28: 182-8. PMID: 19507014
- A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs. | Ishitsuka, Y., et al. 2009. J Pharmacol Sci. 111: 211-5. PMID: 19783866
- Human thromboxane synthase: comparative modeling and docking evaluation with the competitive inhibitors Dazoxiben and Ozagrel. | Sathler, PC., et al. 2014. J Enzyme Inhib Med Chem. 29: 527-31. PMID: 23914925
- Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia. | Bhatia, P., et al. 2021. Vascul Pharmacol. 137: 106827. PMID: 33346090
- Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury. | Terashita, Z., et al. 1995. Thromb Res. 77: 411-21. PMID: 7778056
Inhibitor of:
TXA Synthase, and TXA2R.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ozagrel, 10 mg | sc-200760 | 10 mg | $81.00 | |||
Ozagrel, 50 mg | sc-200760A | 50 mg | $339.00 |